UK's NICE to assess value of medicines from 2014

21 March 2013

The UK drugs watchdog the National Institute for Health and Clinical Excellence (NICE) will take responsibility for assessing the full value of medicines when new pricing arrangements are introduced in 2014, the Ministry of Health announced March 21.

The government confirmed the plans in its official response to the Health Select Committee’s report on the future role of the NICE which has now been published. The move will give the NICE a crucial role in the future value-based pricing arrangements for branded medicines. It will allow the body to build on its current drug evaluation processes by giving it broader scope to assess a medicine’s benefits and costs. The aim is to make sure that the price the National Health Service pays for new medicines is more closely linked to their value to NHS patients and society.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK

More ones to watch >